Stifel analyst Bradley Canino raised the firm’s price target on Janux Therapeutics (JANX) to $115 from $70 and keeps a Buy rating on the shares. The JANX007 Phase 1 update leads the firm to increase its views of the odds of success for second-line and third-line metastatic castration-resistant prostate cancer to 50% and 65%, up from 35% and 50%, respectively, the analyst tells investors. The firm now models risk-adjusted sales of $1.7B from these two opportunities, or $3B unadjusted, the analyst noted.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target raised to $91 from $79 at Leerink
- Janux Therapeutics price target raised to $200 from $100 at Cantor Fitzgerald
- Janux Therapeutics price target raised to $70 from $63 at H.C. Wainwright
- Closing Bell Movers: Zscaler down 8% despite earnings beat
- Janux Therapeutics Reports Promising JANX007 Trial Results